Pembrolizumab + Lenvatinib + Docetaxel
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non-Small Cell Lung Cancer
Conditions
Metastatic Non-Small Cell Lung Cancer
Trial Timeline
Jun 26, 2019 → Aug 22, 2024
NCT ID
NCT03976375About Pembrolizumab + Lenvatinib + Docetaxel
Pembrolizumab + Lenvatinib + Docetaxel is a phase 3 stage product being developed by Eisai for Metastatic Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03976375. Target conditions include Metastatic Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03976375 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Non-Small Cell Lung Cancer